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Abstract
The emergence of influenza viruses resistant to existing classes of antiviral drugs raises concern and there is a need for novel
antiviral agents that could be used therapeutically or prophylacticaly. Surfactant protein D (SP-D) belongs to the family of C-
type lectins which are important effector molecules of the innate immune system with activity against bacteria and viruses,
including influenza viruses. In the present study we evaluated the potential of recombinant porcine SP-D as an antiviral
agent against influenza A viruses (IAVs) in vitro. To determine the range of antiviral activity, thirty IAVs of the subtypes H1N1,
H3N2 and H5N1 that originated from birds, pigs and humans were selected and tested for their sensitivity to recombinant
SP-D. Using these viruses it was shown by hemagglutination inhibition assay, that recombinant porcine SP-D was more
potent than recombinant human SP-D and that especially higher order oligomeric forms of SP-D had the strongest antiviral
activity. Porcine SP-D was active against a broad range of IAV strains and neutralized a variety of H1N1 and H3N2 IAVs,
including 2009 pandemic H1N1 viruses. Using tissue sections of ferret and human trachea, we demonstrated that
recombinant porcine SP-D prevented attachment of human seasonal H1N1 and H3N2 virus to receptors on epithelial cells of
the upper respiratory tract. It was concluded that recombinant porcine SP-D holds promise as a novel antiviral agent against
influenza and further development and evaluation in vivo seems warranted.
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Introduction
IAV are a major cause of respiratory tract infections and cause
excess morbidity and mortality every year. In addition to seasonal
outbreaks of influenza epidemics in the winter months, novel
influenza viruses are occasionally introduced into the human
population and cause pandemics. The introduction of IAV of the
H1N1, H2N2 and H3N2 subtypes have caused pandemics in
1918, 1957 and 1968 respectively. More recently, H1N1 viruses of
swine origin caused the first pandemic of the 21
st century, which
started in Mexico in March 2009 [1,2]. The virus spread rapidly
over all continents and caused disease especially in children and
young adults [3].
In addition, avian IAVs are occasionally transmitted from
infected poultry to man. Especially highly pathogenic avian
influenza viruses of the H5N1 subtype cause infections of humans
relatively frequent and 60% of these cases have a fatal outcome
[4,5].
To protect individuals against seasonal IAV infection, vaccina-
tion is the preventive measure of choice. Especially individuals
with high risk to develop complications of IAV infection benefit
from vaccination, like the elderly, patients with chronic diseases
and immunocompromised individuals. In addition, vaccination
could help to mitigate the impact of a pandemic outbreak.
However, there are three scenarios in which vaccination cannot be
used effectively. First, certain high risk group respond to
vaccination poorly like the frail elderly and certain immunocom-
promised subjects. Secondly, in case of antigenic mis-match, the
vaccine may induce antibodies that fail to neutralize the epidemic
strains optimally and therefore do not afford protection against
theses drift variants [6,7]. Finally, in case of a pandemic the
vaccines may become available too late as was the case during the
2009 pandemic [2].
Under circumstances mentioned above, antiviral drugs may be
used to treat patients infected with IAV and, alternatively, such
drugs can be used prophylactically in outbreak situations.
At present, two classes of licensed antiviral drugs against
influenza exist. The first are the adamantanes (amantadine and
rimantadine) which inhibit the proton-channel function of the
Matrix2 (M2) protein. This protein functions as an ion-channel
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an essential step in the virus replication cycle.
The other class of antiviral drugs comprises the neuraminidase
(NA) inhibitors, zanamivir and oseltamivir. NA acts as a receptor
destroying enzyme and plays a role in the release of viral particles
that bud from infected cells. NA inhibitors are analogs of sialic
acid, the substrate of the enzyme. The use of these drugs reduces
virus replication and may reduce the duration of influenza illness
[8,9,10].
Unfortunately the use of these antiviral drugs also has some
drawbacks. Especially the use of M2 inhibitors may cause some
side effects including neurological and gastrointestinal symptoms.
The main drawback of the use of both M2 and NA inhibitors is the
emergence of resistant strains which are positively selected rapidly.
For example, seasonal H3N2 IAV resistant to amantadine
emerged in 2000 in Asia and is the predominant strain ever since
[11]. Furthermore, 15.5% of the H1N1 viruses were resistant to
adamantanes in 2005–2006 worldwide. In addition, most of the
seasonal H1N1 viruses isolated in the influenza season 2008–2009
were resistant to oseltamivir [11,12,13]. Also during the treatment
of especially immunocompromised patients, which shed virus for
extensive periods, the emergence of resistant strains can be a
complication.
Clearly there is a need for novel drugs that can be used to treat
IAV infection and that do not suffer from these disadvantages.
Therefore, we wished to assess the antiviral properties of
recombinant SP-D from human (RhSP-D) and porcine (RpSP-D)
origin to various IAV and their potential as an antiviral drug. It is
hypothesized that IAV less likely will develop resistance to this
class of antiviral molecules since they target glycans present on
IAV. SP-D belongs to the collectin family, which is an important
class of innate immunity proteins involved in the early response
against pathogens. These collagenous C-type lectins are mainly
produced by Clara cells and type II pneumocytes. They can
neutralize a variety of respiratory pathogens including bacteria
and viruses such as respiratory syncytial virus, parainfluenza virus,
adenoviruses, SARS coronavirus and IAV (for review see [14],
[15]). Collectins can bind glycoconjugates expressed on the surface
of these pathogens via their carbohydrate recognition domains
(CRDs).
The importance of SP-D is demonstrated by studies with SP-D
knock-out mice that are more susceptible to infection with IAV
than SP-D competent mice [16]. Furthermore, it has been shown
that the SP-D concentration increases during IAV infection and
that the administration of an SP-D inhibitor during infection of
mice increased the lung virus titer compared to a normal infection
[17].
The favourable biological properties of SP-D in vivo prompted
further investigation of this molecule as an antiviral drug.
Especially porcine SP-D (pSP-D) showed promising results in
vitro [18,19,20]. It exhibits unique structural features compared to
SP-Ds from other animal species. Unlike its human counterpart, it
contains an extra cysteine in the collagen domain, it is N-
glycosylated with a sialic acid-rich oligosaccharide in the CRD and
there is a potentially important extra loop region (SGA) present in
the CRD which could play a role in the sugar-binding properties
of pSP-D [19]. It was shown with pSP-D isolated from porcine
bronchoalveolar lavage that pSP-D displays a higher affinity to
IAV than human or rat SP-D [19]. Since only a limited number of
IAVs was tested in previous studies, it still remains unknown what
range of IAV strains can be neutralized by pSP-D and by hSP-D.
In the present study, we investigated the potential of RpSP-D
and RhSP-D to neutralize IAVs of the H1N1, H3N2 and H5N1
subtypes.
These findings indicate that RpSP-D has broadly neutralizing
activity and may be a promising candidate as an antiviral drug for
the treatment of IAV.
Materials and Methods
Ethics Statement
The isolation of native SP-D was performed using lungs of
surplus pigs that were euthanized for other purposes. The porcine
lung tissue described in this manuscript was collected from animals
initially used for instructing surgeons specific surgical techniques.
According to the Dutch Experiments on Animals Act an ethical
assessment is required for the primary aim for which experimental
procedures are to be conducted on animals. An ethical assessment
is not mandatory for secondary purpose use of tissues or organs
collected from carcasses. The carcasses were obtained form the
facilities of the Utrecht University, the Netherlands. The Medische
Ethische Toetsings Commissie (METC) of the Erasmus Medical
Center exempted this study from review because according to
dutch law this was not required since the study subjects were not
experimentally treated or asked to change their normal routine
and waived the need of consent due to the fact the samples
received were surplus material from surgical specimens, with
patient identifiers removed and no follow-up information
obtained. These material were obtained from the archive of the
department of Pathology at the Eramus Medical Center in
Rotterdam, the Netherlands.
Viruses
Thirty viruses were selected based on their subtype and species
of origin and included avian swine and human IAV of the H1N1,
H3N2 and H5N1 subtypes. The characteristics of these strains are
listed in table 1. All the viruses were propagated in Madin-Darby
Canine Kidney (MDCK, ATCC CCL-34) cells as described
previously [21]. The culture supernatants of the infected MDCK
were clarified by low speed centrifugation, aliquoted and stored at
280uC until use. Infectious virus titers were determined as
described previously [21].
The three recombinant H5N1 viruses, Indonesia/5/05, Viet-
Nam/1194/04 and HongKong/156/97 were prepared as 6+2
reassortant strains by reverse genetic as described previously [22].
The basic cleavage site in the HA protein was deleted by site-
directed mutagenesis.
Native pSP-D
Native pSP-D (NpSP-D) was isolated from pig lungs as
described previously [23]. For this purpose six months old surplus
pigs were used that were euthanized for other purposes. In short,
NpSP-D was isolated from lung lavage by affinity purification
method using Mannan-sepharose beads. After elution from the
beads with EDTA-containing buffer, NpSP-D was purified using
gel filtration chromatography.
Recombinant porcine and human SP-D
RpSP-D was expressed, purified and characterized as described
by van Eijk et al. (manuscript in preparation) and RhSP-D was
produced based upon the full-length hSP-D clone provided by Dr.
E.C. Crouch (Washington University, St. Louis, USA) [24].
Briefly, SP-D sequence-containing pUPE 101.01 expression
plasmids were transfected into HEK293-EBNA1 cells (ATCC
CRL-10852) using the protocol previously described by Kamen
et al [25]. Expression media were harvested after 5 days, a solution
of CaCl2 was added (10 mM final concentration) and the media
were affinity purified with mannan-agarose. After elution with
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EDTA, pH 7,4), the eluted SP-D was separated by size exclusion
chromatography into differently assembled forms (trimers, dode-
camers). Endotoxin levels were determined with the Toxinsensor
LAL assay kit and ranged between 10–100 pg/mg SP-D.
Hemagglutination Inhibition assay
Binding of SP-D to the viral HA and interference with binding
of the virus to its receptor was assessed by HI. Two-fold dilutions
of SP-D or peanut agglutinin (Sigma Aldrich, Schneeldorf,
Germany), which was included as a negative control, were made
using Dulbecco’s phosphate buffered saline containing PBS
containing 1 mM of CaCl2 and 0.5 mM of MgCl2, PBS-CM
(Gibco, Grand Island, USA). To 100 ml of the diluted SP-D, 2
hemagglutination units (HAU) of the respective viruses diluted in
PBS-CM were added. After 1 h, 25 ml of 1% turkey erythrocytes
were added. The hemagglutination patterns were read after 3 h of
incubation at room temperature. As a negative control, the
experiment was also performed in PBS without CaCl2 to
demonstrate the Ca
2+-dependency of the SP-D activity.
Assessment of binding of RpSP-D to HA
Transient calcium phosphate-mediated transfections of 293T
cells were performed essentiality as previously described [26].
Briefly, 3610
5cells were seeded into wells of 6 well plates and after
16 hours transfected with 5mg of plasmid from which the HA or
NP genes of influenza viruses A/Netherlands/26/07 (H1N1) or
A/Netherlands//178/95 (H3N2). In brief, the plasmid DNA was
mixed with calcium phosphate (0.25M) in a total volume of 50 mL
of water. 50 mL of HBS (1.64% NaCl, 1.18% Hepes and
0.04%Na2PO4, pH=7.12) was added dropwise and the mixture
was left at room temperature for 5 minutes. The DNA mixture
was transferred to 293T cells and incubated overnight at 37uC.
Then, the cells were washed with PBS-CM and incubated with 2
mg of RpSP-D for one hour at 37uC. Cells incubated without
RpSP-D were included as negative controls. After washing with
PBS-CM, the cells were incubated with a monoclonal antibody
directed to pSP-D (AbD serotec, Oxford, UK) diluted 1:100 in
PBS-CM for 30 minutes at room temperature. The cells were
washed with PBS-CM and incubated with a FITC-labeled goat
anti-mouse IgG antibody preparation (AbD Sigma-Aldricht) for 30
minutes at room temperature. After washing the cells were
Table 1. Influenza A viruses used in the present study.
Subtype Classification Strain Abbreviated strain name
Pandemic 2009 A/Netherlands/602/09 NL/09
A/California/4/09 Cali/09
Classical swine A/swine/Shope/11/56 S/Shope/56
A/swine/Iowa/15/30 S/Iowa//30
A/NewJersey/8/76 NJ/76
Avian-like swine A/swine/Netherlands/25/80 S/NL/80
H1N1 A/swine/Netherlands/1/87 S/NL/1/87
Human A/Netherlands/364/06 NL/06
A/Netherlands/246/08 NL/08
A/PuertoRico/8/34 PR8
A/USSR/90/77 USSR/77
Avian A/mallard/Netherlands/15/05 M/NL/15/05
A/mallard/Netherlands/24/06 M/NL/06
A/white fronted goose/Netherlands/1/07 WFG/NL/07
A/common teal/Netherlands/10/00 CT/NL/00
Swine A/swine/Oedenrode/7C/96 S/OR/96
A/swine/Netherlands/849/93 S/NL/93
A/swine/Utrecht/4/85 S/Utrecht/85
A/swine/Ukkel/1/84 S/Ukkel/84
H3N2 Human A/Netherlands/348/07 NL/07
A/Netherlands/548/05 NL//05
A/Netherlands/312/03 NL/03
A/Netherlands/35/93 NL/93
Avian A/mallard/Netherlands/19/05 M/NL/19/05
A/mallard/Netherlands/51/08 M/NL/08
A/mallard/Sweden/51/03 M/Sw/03
A/mallard/Netherlands/1/07 M/NL/07
Clade 0 A/HongKong/156/97 HongKong/97
H5N1 Clade 1 A/VietNam/1194/04 VietNam/04
Clade 2.1 A/Indonesia/5/05 Indonesia/05
doi:10.1371/journal.pone.0025005.t001
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Sliedrecht, Netherlands).
Infection Reduction assay
To determine the neutralizing capacity of RpSP-D an infection
reduction assay was used. To this end, 100 ml of various
concentrations of RpSP-D or peanut agglutinin were incubated
with 100 ml of the respective virus preparations containing
3000TCID50 diluted in PBS-CM for 1 h at room temperature.
Subsequently, the mixture was transferred to MDCK cells, which
were washed with PBS-CM, and incubated for 1 h at 37uC. Then,
the cells were washed once with PBS-CM and twice with PBS
containing 5 mM of EDTA.
The cells were incubated for 24 h at 37uC in culture medium
without trypsin to prevent secondary infection of cells by IAV, and
then washed once with PBS containing EDTA and subsequently
trypsinized. The cell suspensions were transferred to a 96-wells V-
bottom plate and washed twice with PBS containing 2% Fetal
Bovine Serum (P2F). They were stained for viability using
AmCyan-labeled Live/dead staining (Invitrogen, Oregon, USA).
After washing with P2F, the cells were fixed with 100 ml of cytofix
(BD Biosciences, San Diego, CA) according to the manufacturer
recommendations. Subsequently, the cells were washed twice with
cytoperm (BD Biosciences, San Diego, CA) and incubated with a
monoclonal antibody specific for the viral nucleoprotein, labeled
with fluorescein isothiocyanate, FITC, (DAKOCytomation,
Glostrup, Denmark). After washing twice with P2F, the cells were
analyzed by flow-cytometry using the DIVA software.
Virus histochemistry
For virus histochemistry the seasonal IAVs A/Netherlands/35/
05 (H1N1) and A/Netherlands/231/03 (H3N2) were used. These
viruses were propagated in MDCK cells and purified by sucrose
gradient density centrifugation. They were incubated in formalin
for one week and then labeled with FITC (Sigma-Aldrich, Saint
Louis, MO) as described previously [27]. Archival paraffin-
embedded human tracheal tissue sections were obtained from
the Department of Pathology, Erasmus MC. Ethics approval was
not required because it concerned surplus material from surgical
specimens, with patient identifiers removed and no follow-up
information obtained. Archival paraffin-embedded ferret tracheal
tissue sections were obtained from the Department of Virology,
Erasmus MC. The assessment of virus binding to the trachea tissue
was performed essentially as described previously [27]. In brief,
FITC-labeled virus was incubated with the tissue sections and
binding of virus was detected using a peroxidase labeled rabbit
anti-FITC antibody preparation (DAKOCytomation, Glostrup,
Denmark) and the signal was amplified with a tyramide signal
amplification system (Perkin Elmer, Boston, MA).
Various concentrations of RpSP-D, peanut agglutinin (negative
control), pokeweed (negative control) or Concanavalin A (ConA)
(positive control) were incubated with 40 HAU of virus for 1 h. All
dilutions were made in PBS-CM.
The tissue sections were first deparaffinized with xylene and
hydrated with ethanol. Then, they were incubated with 3% H2O2
for 10 min and subsequently incubated with Tris -HCl pH 7.5
containing 0.5% blocking reagent buffer (Perkin Elmer, Boston,
MA). Then the tissue sections were incubated with FITC-labelled
virus for 1 h in the absence or presence of RpSP-D or one of the
other lectins for 1 h. After washing the slides with PBS containing
5 mM of EDTA and 0.05% Tween they were further developed.
The tissues were counterstained with haematoxylin and embedded
in glycerol-gelatin (Merck, Whitehouse Station, NJ).
Neuraminidase Inhibition assay
To exclude steric hindrance from binding to the HA,
recombinant NA was used in the NA inhibition assay. Tetrameric,
GCN4 stabilized, soluble recombinant NA derived from A/
Victoria/3/75 (H3N2) and A/crested eagle/Belgium/01/2004
(H5N1, cDNA kindly provided by Dr. Thierry van den Berg,
VAR, Brussels) virus were expressed and purified from a
recombinant baculovirus expression system in Sf/9 cells, as
described [28,29]. In brief, after baculovirus infection, Sf/9 cell
culture medium was harvested, passed through a 0.22 mm filter
and extracted with 3/5 volumes of n-butanol. The aquous phase,
containing NA, was adjusted to 5 mM KH2PO4 pH 6.6 and
loaded on a hydroxyapatite column, equilibrated with 5 mM
KH2PO4 pH 6.6, 4% butanol. The column was eluted using a
linear gradient of 5 mM KH2PO4 pH 6.6, 4% butanol to
400 mM KH2PO4 pH 6.6, 1% butanol. NA-containing fractions
were pooled and subsequently loaded on a Blue sepharose column,
followed by a wash step with 50 mM MES pH 6.6, 5% glycerol,
8 mM CaCl2. The Bleu sepharose column was eluted with 50 mM
MES pH 6.6, 5% glycerol, 8 mM CaCl2, 1.5 M NaCl. In a final
polishing step, the NA was fractionated on a Superdex200 pg
column, equilibrated with 50 mM MES pH 6.6, 5% glycerol,
8 mM CaCl2, 150 mM NaCl. Purified recombinant N1 and N2
NA were aliquoted and stored at 280 uC before use.
The neuraminidase inhibition assay was adapted from the
WHO protocol [30]. Shortly, 16 ng of N1 or N2 were incubated
overnight with the various concentration of RpSP-D, Concanav-
alin A (positive control, [31]) or peanut agglutinin (negative
control) (Sigma Aldrich Chemie BV, Germany, Steinheim) and
25 ml of fetuin in micronic tubes. Volume was adjusted to 75 uL
with PBS-CM. On the next day, 5 ml of periodate reagent (4.28 g
of sodium meta-Periodate in 38 ml H2O) (Merck-Schuchardt,
Germany, Hohenbrunn) was added and the mixture was
incubated for 15 min at room temperature. Then 25 ml of arsenite
reagent (10 g sodium arsenite, 7.1 g anhydrous sodium sulfate and
100 ml H2O) (E Merck, Germany, Darmstadt) was added and
mixed to the rest until the brown color disappeared. The mixtures
were transferred to a PCR plate. Then 50 ml of thiobarbituric acid
reagent (35.5 g anhydrous sodium sulfate, 3.0 g thiobarbituric acid
and 500 ml H2O) (Sigma Aldrich Chemie BV, Germany,
Steinheim) was added and incubated for 15 min at 99uC and
30 min on ice. The mixtures were transferred to micronic tubes,
200 ml of Warrenhoff reagent was added and each tube was
vortexed. Finally, the tubes were centrifuged for 5 min at
2000 rpm and 100 ml of the upper butanol phase was transferred
to an ELISA plate to measure the optical density with a
spectrophotometer (Infinite M200, Tecan) at wavelength
549 nm. The percentage of inhibition was calculated according
to the formula, (1-(Absorbance (sample)/Absorbance (without
inhibitor)) x100%.
Results
Biological activity of RpSP-D resembled that of NpSP-D
First, we investigated whether RpSP-D had similar biological
activity against IAV compared to NpSP-D isolated from pig lungs.
To this end, the two preparations were tested against 15 H1N1
and 12 H3N2 IAV of swine, human and avian origin. HI assays
were performed three times independently and the results are
shown in figure 1. RpSP-D inhibited hemagglutination by IAV to
a similar extent as NpSP-D and statistical differences were not
observed. Furthermore, the activity of both preparations was
shown to be dependent on the presence of calcium ions, since no
inhibition was observed in PBS without CaCl2. In this assay,
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inhibit IAV-mediated hemagglutination.
Influenza A viruses of different subtypes are recognized
differentially by RpSP-D
The minimal concentration of RpSP-D that still prevented
hemagglutination by each of the viruses tested was determined.
Each assay was performed in duplicate and repeated three to six
times and the average minimal inhibitory concentration of RpSP-
D was calculated for each virus and plotted in figure 2A–D.
On average, less RpSP-D was required to prevent hemagglu-
tination by IAV (swine human and avian) of the H3N2 subtype
(25 ng/100 ml) than those of the H1N1 (187 ng/100 ml) or H5N1
(3167 ng/100 ml) subtype (figure 2A).
Within the H1N1 and H3N2 subtypes, differences in sensitivity
for the inhibitory activity of RpSP-D existed, depending on the
species the viruses originated from. Apart from PuertoRico/8/34,
human IAVs of the H1N1 subtype were susceptible to the
inhibitory activity of RpSP-D. On average, 17 ng/100 ml was
already sufficient to fully inhibit hemagglutination against the
human H1N1 IAVs (excluding PuertoRico/8/34). For avian,
avian-like swine and classical swine viruses of the H1N1 subtype
these concentrations were higher, 183 ng/100 ml, 120 ng/100 ml
and 342 ng/100 ml respectively (figure 2B). The classical swine
virus Swine/Iowa/15/30 was not susceptible to inhibition by
RpSP-D at the maximum concentration tested (.500 ng/100 ml).
Also the 2009 pandemic H1N1 strains, California/4/09 and
Netherlands/602/09 were relatively susceptible; the average
inhibitory concentration was 304 ng/100 ml (figure 2B).
Also within the H3N2 subtypes, the human-derived strains were
more susceptible than the avian and swine viruses with minimal
inhibitory concentrations of 11 ng/100 ml, 14.6 ng/100 ml and
51 ng/100 ml respectively (figure 2C).
All viruses of the H5N1 subtype tested, HongKong/156/97
(clade0), VietNam/1194/04 (clade1) and Indonesia/5/05
(clade2.1) were not in particular susceptible and high concentra-
tions of RpSP-D were required to prevent the hemagglutination by
these viruses (4500 ng/100 ml, 2000 ng/100 ml and 3000 ng/
100 ml respectively) (figure 2D).
RpSP-D multimers inhibit IAV more efficiently than
trimers
HEK293 cell-derived RpSP-D and RhSP-D preparations were
assembled in two forms: partly assembled trimeric subunits and
fully-assembled oligomeric forms of trimers referred to as multi-
mers. After separation of these two forms by gel filtration
chromatography, the inhibitory capacity of both forms was
compared with the respective viruses in the HI assay.
As shown in figure 2D, E and F, the specific biological activity of
the multimers was greater than that of the trimers. On average,
39.8 ng/100 ml of RpSP-D multimers was required to inhibit
hemagglutination by all influenza A/H1N1 viruses tested, which
was significantly lower (p=0.001, Mann-Whitney test) than the
minimal inhibitory concentration of the trimers (601.5 ng/100 ml).
Influenza virus A/swine/Netherlands/1/87 was not inhibited by
the trimers of RpSP-D at the minimal concentration tested
(1600 ng/100 ml) (figure 2E). Also for the inhibition of all the
influenza A/H3N2 viruses tested the minimal inhibitory concen-
tration of multimers was significantly lower (p=0.002, Mann-
Whitney test) than that of the trimers (8.7 ng/100 ml 124 ng/
100 ml respectively) (figure 2F).
The minimal inhibitory concentration of multimers required to
inhibit the H5N1 viruses was 1400 ng/100 ml whereas the trimers
of RpSP-D failed to inhibit these viruses at the maximum
concentration tested (.4500 ng/100 ml) (Figure 2D).
Comparison of RpSP-D and RhSP-D
Although RpSP-D and RhSP-D have similar structures, there
are also some striking differences. Therefore we compared the
inhibitory capacity of SP-D derived from these two species in the
HI assay using a panel of altogether 27 of H1N1 and H3N2 IAVs.
It was found that RpSP-D inhibited IAV of the H1N1 subtype
more efficiently than RhSP-D. RhSP-D failed to inhibit the
hemagglutination by most H1N1 viruses at the maximum
concentration tested (.7500 ng/100 ml) (figure 3A). The minimal
inhibitory concentration of RpSP-D ranged from 4 ng/100 mlt o
318 ng/100 ml.
A similar pattern was observed for the inhibition of the all A/
H3N2 viruses tested of which some were inhibited by RhSP-D,
albeit at relatively high concentrations ranging from 427 ng/
100 ml to 6666 ng/100 ml (figure 3B). In comparison, RpSP-D
inhibited hemagglutination by H3N2 efficiently. For all H1N1 and
H3N2 viruses, the differences in minimal inhibitory concentration
between RpSP-D and RhSP-D were statistically significant
(p,0.05). In all cases where inhibition was observed by RhSP-D
or RpSP-D, the action of SP-D was dependent on the presence of
calcium ions (data not shown). To test whether multimers of
RhSP-D would be more potent than the trimeric RhSP-D forms,
the inhibitory capacity of RhSP-D multimers was compared to
that of the trimers (figure 3C) using a selection of H1N1 and
Figure 1. Antiviral activity of RpSP-D resembles that of NpSP-
D. The minimal inhibitory concentration of RpSP-D and NpSP-D
required to inhibit the hemagglutination by all 27 H1N1 and H3N2
IAVs was assessed (A). The horizontal line indicates the average of the
minimal inhibitory concentration for both preparations which did not
differ significantly. The values were also compared directly (B). The
minimal inhibition concentrations of RpSP-D correlated well with those
of NpSP-D. Each symbol in panels A and B represent an individual IAV
strain.
doi:10.1371/journal.pone.0025005.g001
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(Netherlands/312/03 and Netherlands/348/07), the minimal
inhibitory concentration of multimers was only slightly lower than
that of trimers, indicating that the modest inhibitory capacity of
RhSP-D was not caused by absence of multimers in the RhSP-D
preparation.
RpSP-D binds to HA
Using immuno-fluorescence, we demonstrated that RpSP-D
can bind to HA of human influenza viruses. 293T cells were
transfected with plasmids from which the HA and NP genes of
influenza virus A/Netherlands/178/95 (H3N2) were expressed.
Using a SP-D specific monoclonal antibody, binding of RpSp-D
was observed to cells transfected with the plasmid expressing the
HA gene but not with cells transfected with a plasmid encoding the
NP gene (Figure 4). Without RpSP-D, no fluorescence was
observed confirming the specificity of the staining. With plasmids
encoding the HA and NP genes of influenza virus A/Netherlands/
26/07 (H1N1) similar results were obtained (data not shown).
RpSP-D inhibits MDCK cells infection with IAV
Using an infection reduction assay, the capacity of RpSP-D to
protect MDCK cells from infection with the respective viruses was
tested. Peanut agglutinin, which was included as a negative control,
failed to reduce the number of cells infected with any of the IAVs
used (data not shown). In contrast, RpSP-D inhibited infection of
Figure 2. RpSP-D inhibits the hemagglutination by a broad range of IAVs. The minimal inhibitory concentration of RpSP-D that still
inhibited the hemagglutination by a variety of IAV was determined. In panel A, the bars represent the average minimal concentration of RpSP-D
required to inhibit all H1N1, H3N2 and H5N1 viruses tested, independent of the animal species they originated from. Panels B and C show the results
of individual H1N1 (B) and H3N2 (C) viruses and their origin. The average concentrations obtained in six independent experiments are shown. The
results obtained in four independent experiments with H5N1 viruses, VietNam/04 (open square), Indonesia/05 (closed diamond), HongKong/97
(closed triangle) are shown in panel D. Also the results (the average of three independent experiments) are shown in panel E and F for inhibition by
multimers and trimers of RpSP-D. The H1N1 viruses tested are NL/09 (closed diamond), S/NL/1/87 (closed triangle), NJ/76 (closed square), NL/06
(open square), M/NL/06 (closed circle), NL/08 (open circle), WGF/NL/07 (open triangle) (panel E) and the H3N2 viruses tested are S/NL/93 (closed
diamond), NL/07 (open square), NL/03 (open triangle), NL/93 (closed triangle), M/NL//08 (open circle), M/Sweden/03 (closed circle), M/NL/07 (closed
square) (panel F).
doi:10.1371/journal.pone.0025005.g002
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H5N1 subtype (Figure 5). For most IAV strains tested, a dose-
dependent reduction of the number of infected cell was observed.
In this cellular infectivity assay, none of the viruses tested were
fully inhibited by SP-D. At the highest concentration tested
(1000 ng/200 ml), on average 77.7% inhibition was observed for
the pandemic 2009 H1N1 viruses, 47.2% for the classical swine
viruses, 24.9% for the avian-like swine viruses and 68.5% for the
human seasonal H1N1 viruses (except A/PuertoRico/8/34).
Viruses of the H3N2 subtype were inhibited more efficiently
and at the highest dose of RpSP-D tested, 84.9% inhibition was
achieved for the swine H3N2 viruses, 72.9% for the human and
52.3% for the avian H3N2 viruses. At the lowest concentration
tested (2 ng/200 ml) a reduction of infection of 45.6% was
observed with the human H3N2 viruses and 29.6% with the
human H1N1 viruses.
The viruses of the H5N1 subtype were poorly inhibited even
when a high concentration of RpSP-D was used (5000 ng/200 ml).
IAV strain VietNam/1194/04 was not inhibited at all while for
HongKong/156/97 and Indonesia/5/05 only 10% and 34%
inhibition was observed, respectively.
RpSP-D inhibits the enzymatic activity of the viral
neuraminidase
We also determined whether RpSP-D can interact with NA and
is able to inhibit its enzymatic activity. To this end, purified
recombinant neuraminidase of the N1 and N2 subtype instead of
virion-exposed NA was used to exclude possible steric hindrance of
the binding of RpSP-D to HA.
As shown in figure 6, peanut agglutinin did not inhibit the
enzymatic activity of neuraminidase significantly.
In contrast, both RpSP-D and ConA inhibited enzymatic
activity of both subtypes of NA tested, although relatively high
doses of RpSP-D were required to achieve maximal inhibition.
A concentration of 50 mg/100 ml inhibited the enzymatic
activity the NA of A/crested eagle/Belgium/01/2004 (H5N1) by
85% and the activity of A/Victoria/3/75(H3N2) by 75%. As
expected, oseltamivir inhibited neuraminidase activity efficiently
(figure 6). In the assay used, oseltamivir inhibited 75% of the
enzymatic activity the N1 molecule and 48% of the N2 molecule
at a concentration of 10 nM.
RpSP-D inhibits binding of virus to ciliated epithelial cells
of ferret and human trachea
To be effective as an antiviral drug, RpSP-D must be able to
interfere with binding of virus to cells of the respiratory tract.
Therefore, we tested the capacity of RpSP-D to inhibit attachment
of a human seasonal H1N1 and a human seasonal H3N2 virus to
tracheal epithelial virus cells using virushistochemistry.
As shown in figure 7A, both viruses bind to epithelial cells of
ferret trachea which is visible as red precipitate. Preincubation of
FITC-labeled virus with RpSP-D prevented binding at a minimal
dose of 0.1 mg for the H1N1 virus and 10 mg for the H3N2 virus.
A dose of 1 mg did not prevent the binding of the H3N2 virus
completely but the number of positive cells was reduced compared
to that after incubation of labeled virus in the absence of RpSP-D.
The inhibition of virus attachment was dependent on the presence
of Ca
2+-ions, since in the absence of CaCl2, a dose of 10 mg RpSP-
D failed to prevent attachment of both viruses.
Two control lectins, peanut agglutinin and pokeweed mitogen,
failed to prevent virus attachment. In contrast, ConA, which was
included as a positive control since it has high affinity for the viral
hemagglutinin, blocked virus attachment at a concentration of
1 mg/150 ml (data not shown).
We also tested the effect of RpSP-D on virus attachment using
human trachea tissue (figure 7B). At a dose of 10 mg, RpSP-D fully
prevented binding of human seasonal H1N1 and H3N2 IAV. At a
dose of 1 mg, binding of virus to epithelial cells was reduced
considerably compared to virus attachment in the absence of
RpSP-D.
Discussion
In the present study, the antiviral activity of RpSP-D was
assessed against a wide range of IAV strains.
Figure 3. Comparison between the HI activity of RpSP-D and
that of RhSP-D. The minimal inhibitory concentrations of RpSP-D
(black bars) and RhSP-D (white bars) were determined with the HI assay
for the H1N1 (A) and H3N2 (B) viruses as indicated. In panel C, the
minimal inhibitory concentrations of RhSP-D multimers (black bars) and
trimers (white bars) were compared. The data represent the average of
three independent experiments.
doi:10.1371/journal.pone.0025005.g003
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defense molecules of the innate immune system [14]. For the
development of a collectin-based antiviral drug, the use of a well-
defined recombinant product is the most acceptable venue.
However, the biological properties of the recombinant protein
need to resemble those of the native protein. First, the biochemical
properties of RpSP-D were characterized in detail and compared
with NpSP-D and it was shown that RpSP-D is structurally and
functionally identical to NpSP-D (van Eijk et al., manuscript in
preparation). In this study, we focused on the antiviral properties
of RpSP-D and compared its IAV-neutralizing activity with that of
NpSP-D isolated from pig lungs in the HI assay against a broad
panel of IAV strains. The inhibitory activity of both preparations
was comparable and dependent on the presence of calcium ions,
indicating that we were able to produce a biological active and
properly folded recombinant protein.
We also compared the antiviral activity of RpSP-D with that of
RhSP-D. In general, RpSP-D had a more potent antiviral activity
than RhSP-D as measured in the HI assay. For example, the two
2009 H1N1 pandemic strains were not susceptible to inhibition by
RhSP-D, which is in agreement with a previous study [32]. In
contrast, RpSP-D did inhibit hemagglutination by 2009 H1N1
viruses although relatively high doses were required. Furthermore,
RhSP-D failed to inhibit the hemagglutination by swine IAV of
the H1N1 subtype. Avian H3N2 and human H3N2/H1N1 viruses
were inhibited inefficiently since at least 100-fold more RhSP-D
than RpSP-D was required.
Thus it was concluded that RpSP-D inhibited a broader range
of IAVs and more effectively than RhSP-D and was therefore
studied in more detail.
RpSP-D not only inhibited hemagglutination by most H1N1
and H3N2 viruses, it also reduced infection of MDCK cells by
these viruses. Only viruses of the H5N1 subtype were inhibited
inefficiently and very high doses were required to observe
inhibition in both assays. RhSP-D also failed to neutralize viruses
of this subtype as demonstrated previously [33].
It is of interest to note that human H1N1 and H3N2 viruses
were more susceptible to the action of RpSP-D and RhSP-D than
those originating from pigs and birds species.
These differences may be explained by differences in glycosyl-
ation. The HA of human IAV contains more putative N-linked
glycosylation sites than avian and swine viruses allowing SP-D to
interact with the HA more efficiently through its CRD domain as
was shown for RhSP-D [32,33,34].
The potency of RpSP-D was superior to that of RhSP-D, which
may be explained by structural differences. Compared to RhSP-D,
RpSP-D has an additional loop in its CRD, an additional
glycosylation site and an additional cysteine in the collagen
domain. It has been shown that the sialic acid-rich N-linked glycan
in the CRD provides an additional mode of interaction, most likely
with the sialic acid receptor present at the tip of the viral
hemagglutinin molecule [20]. However the contribution of each of
these features to the superior antiviral activity of RpSP-D needs to
be further elucidated.
The observation that fully assembled RpSP-D neutralizes IAV
better than the trimeric form is in line with the reasoning
mentioned above. Most likely multimerisation increases the avidity
of the SP-D molecules, by increasing the number of CRDs that
can interact with IAV simultaneously.
Another potential viral target that could be bound or inhibited
by RpSP-D is the NA of IAV. It has been shown previously that
inhibition of the enzymatic activity of NA successfully inhibited
virus replication and viral spread and a class of existing antiviral
drugs is based on this principle. To investigate whether IAV NA,
which is also glycosylated, can be inhibited by RpSP-D, we used,
in contrast to other studies [33,35], recombinant NA molecules to
exclude the interference of the enzymatic activity by binding of
RpSP-D to HA. Although the enzymatic activity was inhibited to a
certain extent, relatively high RpSP-D doses were required to
achieve this. We therefore conclude that binding of RpSP-D to the
viral HA most likely is a more potent mode of antiviral action than
binding to NA. Of note, the reduction of infection of MDCK cells
that was observed correlated with the inhibition of the hemagglu-
tination activity of IAV. This provides additional evidence that
HA is the primary target of RpSP-D. The interaction of RpSP-D
with the viral HA, prevents the attachment of the virus to target
cells and is at the basis of the neutralizing effect of RpSP-D.
Indeed, we demonstrated that RpSP-D is able of binding HA of
influenza A viruses of the H1N1 and H3N2 subtype (Figure 4).
Figure 4. RpSP-D binds to HA. 293T cells were transfected with plasmids expressing HA or NP genes derived from influenza virus A/Netherlands//
178/95 (H3N2). The cells were then incubated with RpSP-D or not and binding of RpSP-D was assessed by an immuno-fluorescence assay (upper
panels) using a mouse monoclonal anti-pSP-D antibody and a goat anti-mouse FITC labeled antibody. Cells were analyzed using a fluorescence
microscope. No binding of RpSP-D was detected in cells transfected with a plasmid encoding the NP gene, which was included as negative control,
whereas cells expressing the HA gene bound RpSP-D.
doi:10.1371/journal.pone.0025005.g004
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virushistochemistry we demonstrated that RpSP-D could reduce
binding of human IAV H1N1 and H3N2 viruses to epithelial cells
of the human and ferret upper respiratory tract. The binding of
virus to paraffin-embedded tissues may not reflect the virus-tissue
interaction in vivo exactly. However, the binding patterns of various
influenza viruses to respiratory tract tissue obtained from various
animal species correlate with pathogenesis and transmissibility of
these viruses. This indicates that the patterns of virus-tissue
binding assessed by our virushistochemistry method has biological
relevance [27,36,37,38].
In conclusion, the results obtained in the present study showed
that RpSP-D has potent antiviral activity against a wide range of
IAV strains in vitro. RpSP-D had broad neutralizing activity against
Figure 5. Reduction of IAV infection by RpSP-D. Using the infection reduction assay, the neutralization of IAV by various doses of RpSP-D was
assessed. The reduction of infectivity was expressed as the relative number of cells that became infected according to the formula: % reduction=
1-(% infected cells in presence of RpSP-D/% infected cells without RpSP-D)*100%. The viruses were grouped by subtype and origin: swine H3N2 (A),
human H3N2 (B), avian H3N2 (C), 2009 pandemic H1N1 (D), avian-like swine H1N1 (E), classical swine (F), human H1N1 (G), avian H1N1 (H) and H5N1
(I). The average of triplicate wells is shown.
doi:10.1371/journal.pone.0025005.g005
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PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e25005Figure 6. Inhibition of neuraminidase activity by RpSP-D. The enzymatic activity of recombinant purified neuraminidase derived from IAV
strains A/crested eagle/Belgium/01/2004 (N1) (A) and A/Victoria/3/75 (N2) (B) was determined after overnight incubation in the presence of various
doses of peanut agglutinin (open square), ConA (open circle), oseltamivir (closed circle) or RpSP-D (closed triangle). The concentration is expressed in
mg/100ml for the lectins and in nM for oseltamivir. NA activity in the absence of inhibitors was normalized to 100% and the percentage of inhibition
was depicted.
doi:10.1371/journal.pone.0025005.g006
Figure 7. RpSP-D prevents binding of human seasonal H1N and H3N2 viruses to epithelial cells of ferret and human trachea.
Attachment of virus in absence or presence of RpSP-D was studied by virushistochemistry. Sections of ferret trachea (A) or human trachea (B) were
incubated with FITC-labeled IAV A/Netherlands/35/05 (H1N1) and A/Netherlands/231/03 (H3N2) in the absence or presence of various doses of
RpSP-D as indicated. Binding of virus is visible as dark-red staining. As a negative control, the highest dose of RpSP-D (10 mg) was also measured in
absence of calcium ions. The tissues were counterstained with hematoxylin (magnification x100).
doi:10.1371/journal.pone.0025005.g007
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e25005IAVs which were neutralized differentially, depending on subtype
and animal species of origin. The antiviral effect is mostly
mediated by binding of RpSP-D to the viral HA, thereby
preventing it from binding to the host cells receptors as was
demonstrated by virushistochemistry using ferret and human
trachea tissue. Future studies will aim at the delivery of RpSP-D
and assessing its antiviral properties in vivo.
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